Paper Details

  1. Home
  2. Paper Details

[A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].

Author: GuanZ, LinT, WuH

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Paclitaxel is effective with tolerable side effects for treating advanced malignancies. The overall response rate was 46.7% for ovarian cancer, 56.4% for breast cancer, 25.0% for non-small-cell lung cancer, 66.7% for small-cell lung cancer, and 41.7% for nasopharyngeal cancer.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy and toxicity of China-made paclitaxel in patients with a variety of advanced malignancies. METHODS: Paclitaxel was administered by i.v. infusion at a dose of 175 mg/m2 in 3-hour every three weeks. All patients received premedication(dexamethasone, diphenhydramine...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/10920970

データ提供：米国国立医学図書館（NLM）

A Phase II Clinical Study of China-Made Paclitaxel in the Treatment of Cancer Patients

Cancer is a vast and challenging desert, and researchers are always searching for new ways to combat this formidable enemy. This study investigates the efficacy and toxicity of [China-made paclitaxel] in treating patients with various [advanced malignancies]. The study used a [phase II clinical trial] design to evaluate the drug’s effectiveness and safety in a real-world setting.

The study, which involved [116 patients] with advanced cancers, found that China-made paclitaxel demonstrated significant efficacy in treating various cancers, including [ovarian, breast, non-small-cell lung, small-cell lung, and nasopharyngeal cancers]. The drug showed promising response rates, indicating its potential as a viable treatment option for these challenging cancers. The study also evaluated the safety profile of China-made paclitaxel, finding that it was generally well tolerated with manageable side effects.

A Potential Treatment Option for Advanced Cancers

The results of this study suggest that China-made paclitaxel could be a valuable addition to the treatment options for advanced cancers. The drug’s efficacy in treating various cancers, coupled with its manageable side effects, makes it a promising candidate for further investigation.

Implications for Cancer Treatment and Quality of Life

The development of effective and safe treatments for advanced cancers is crucial for improving the lives of patients. China-made paclitaxel offers a potential solution for individuals facing these challenging diagnoses. By providing effective treatment options, we can improve the quality of life for cancer patients and give them hope for the future.

Dr.Camel's Conclusion

This study is a ray of hope in the desert of cancer research. The findings suggest that China-made paclitaxel could be a valuable tool in the fight against advanced cancers. While more research is needed to fully understand the long-term effects of this drug, it offers a promising treatment option for individuals facing this formidable disease.

Date :
  1. Date Completed 2000-08-11
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

10920970

DOI: Digital Object Identifier

10920970

Related Literature

Article Analysis
・Side Effects of cimetidine
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.